AA
RLAY icon

ALPS Advisors’s Relay Therapeutics RLAY Stock Holding History

ALPS Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.12M Buy
220,386
+74,896
+51% +$1.09M 0.02% 326
2026
Q1 		$1.45M Buy
145,490
+3,169
+2% +$28.4K 0.01% 474
2025
Q4 		$1.2M Buy
142,321
+59,896
+73% +$427K 0.01% 499
2025
Q3 		$430K Sell
82,425
-10,103
-11% -$38.5K ﹤0.01% 874
2025
Q2 		$320K Buy
+92,528
New +$275K ﹤0.01% 912

Other funds holding RLAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

ALPS Advisors's RLAY Position: Q2 2026 in Review

ALPS Advisors increased its Relay Therapeutics (RLAY) stake by 51% in Q2 2026, buying an estimated $1.09M and bringing the position to 220,386 shares worth $4.12M. The position accounts for 0.02% of the portfolio, ranked #326.

ALPS Advisors first reported a position in RLAY in Q2 2025 and has held it in 5 quarters since. 74 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • ALPS Advisors held 220,386 shares of Relay Therapeutics worth $4.12M as of Q2 2026.
  • ALPS Advisors bought 74,896 Relay Therapeutics shares in Q2 2026, an estimated $1.09M.
  • Relay Therapeutics made up 0.02% of ALPS Advisors's portfolio in Q2 2026, its #326 holding.
  • ALPS Advisors first reported a position in Relay Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 74 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.